Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

@article{Cai2015TreatmentOP,
  title={Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.},
  author={Qingxian Cai and Fengjuan Chen and Xiaoqiong Shao and Xiaohong Zhang and Zhixin Zhao and Zhi-Liang Gao},
  journal={Antiviral therapy},
  year={2015},
  volume={20 2},
  pages={217-24}
}
BACKGROUND Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients. METHODS A total of 74 hepatitis B e antigen (HBeAg)-positive patients with a spontaneous HBV DNA decline (by >2 log10 IU•ml(-1), compared with baseline levels before antiviral treatment) after AE (alanine… CONTINUE READING